1. Scrip
  2. >>Business

Preparing Emerging Biotechs For The Best Deals – Insider Insights

 
• By Lucie Ellis-Taitt

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Red arrow
Getting ahead: top tips for early-stage companies seeking deals in the competitive biopharma market • Source: Shutterstock

Market experts are predicting more biopharma transactions in 2018 compared with last year, but positioning start-ups and emerging companies for the best deals is a tricky business. Scrip has collected advice from industry experts on how to value non-profit-making businesses and gathered tips on the best way to capture the attention of potential partners or buyers.

Albert Sokol, a partner at US law firm McDermott Will & Emery, highlights the challenges surrounding deal structures that include...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut